CA2620132C - Lactoferrin complex and method of producing the same - Google Patents
Lactoferrin complex and method of producing the same Download PDFInfo
- Publication number
- CA2620132C CA2620132C CA2620132A CA2620132A CA2620132C CA 2620132 C CA2620132 C CA 2620132C CA 2620132 A CA2620132 A CA 2620132A CA 2620132 A CA2620132 A CA 2620132A CA 2620132 C CA2620132 C CA 2620132C
- Authority
- CA
- Canada
- Prior art keywords
- lactoferrin
- complex
- hydrophilic polymer
- poly
- peptide hydrophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005-258103 | 2005-09-06 | ||
| JP2005258103A JP4261531B2 (ja) | 2005-09-06 | 2005-09-06 | ラクトフェリン複合体及びその製造方法 |
| PCT/JP2006/316367 WO2007029484A1 (ja) | 2005-09-06 | 2006-08-22 | ラクトフェリン複合体及びその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2620132A1 CA2620132A1 (en) | 2007-03-15 |
| CA2620132C true CA2620132C (en) | 2017-11-21 |
Family
ID=37835608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2620132A Expired - Fee Related CA2620132C (en) | 2005-09-06 | 2006-08-22 | Lactoferrin complex and method of producing the same |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8673839B2 (enExample) |
| EP (1) | EP1932855B1 (enExample) |
| JP (1) | JP4261531B2 (enExample) |
| CA (1) | CA2620132C (enExample) |
| WO (1) | WO2007029484A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2000447A4 (en) | 2006-03-24 | 2012-07-25 | Ngk Insulators Ltd | SINTER BODY, LIGHT EMISSION STROKE AND MANUFACTURING METHOD THEREFOR |
| US20110009313A1 (en) * | 2008-03-14 | 2011-01-13 | Nrl Pharma, Inc. | Polyethylene glycolated lactoferrin complex and method of producing the same |
| JP2009221159A (ja) * | 2008-03-17 | 2009-10-01 | Yokohama Tlo Co Ltd | Ｐｅｇ化ラクトフェリンを主成分とする医薬製剤 |
| US8614189B2 (en) * | 2008-09-24 | 2013-12-24 | University Of Connecticut | Carbon nanotube composite scaffolds for bone tissue engineering |
| WO2011081915A2 (en) * | 2009-12-15 | 2011-07-07 | Cebix Inc. | Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
| WO2011143187A2 (en) | 2010-05-10 | 2011-11-17 | University Of Connecticut | Lactoferrin -based biomaterials for tissue regeneration and drug delivery |
| JP2013533217A (ja) | 2010-05-17 | 2013-08-22 | セビックス・インコーポレイテッド | Ｐｅｇ化ｃ−ペプチド |
| EP2441443A1 (en) | 2010-10-07 | 2012-04-18 | Nestec S.A. | Lactoferrin based complex coacervates and their uses |
| US8962553B2 (en) | 2011-11-17 | 2015-02-24 | Cebix Ab | Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide |
| JP5855239B2 (ja) | 2012-04-23 | 2016-02-09 | 株式会社Ｎｒｌファーマ | ラクトフェリン融合タンパク質及びその製造方法 |
| US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
| CA2911483C (en) | 2013-04-09 | 2022-10-04 | The University Of Tokyo | Inhibitor of extracellular trap formation in leukocytes |
| EP3533870A4 (en) | 2016-10-28 | 2020-04-08 | NRL Pharma, Inc. | LACTOFERRIN / ALBUMIN FUSION PROTEIN AND PROCESS FOR PRODUCING THE SAME |
| WO2020096672A1 (en) | 2018-11-09 | 2020-05-14 | The Wistar Institute Of Anatomy And Biology | Use of lactoferrin for generating myeloid-derived suppressor cells |
| CN120754233A (zh) * | 2025-07-16 | 2025-10-10 | 南京财经大学 | 一种牛乳铁蛋白复合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6046305A (en) | 1997-12-12 | 2000-04-04 | Macromed, Inc. | Heterofunctionalized star-shaped poly(ethylene gycols) for protein modification |
| WO2000024697A1 (en) * | 1998-10-26 | 2000-05-04 | University Of Utah Research Foundation | Method for preparation of polyethylene glycol aldehyde derivatives |
| US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| JP2005258103A (ja) | 2004-03-12 | 2005-09-22 | Kyocera Mita Corp | 画像形成装置 |
-
2005
- 2005-09-06 JP JP2005258103A patent/JP4261531B2/ja not_active Expired - Fee Related
-
2006
- 2006-08-22 CA CA2620132A patent/CA2620132C/en not_active Expired - Fee Related
- 2006-08-22 US US12/065,877 patent/US8673839B2/en not_active Expired - Fee Related
- 2006-08-22 WO PCT/JP2006/316367 patent/WO2007029484A1/ja not_active Ceased
- 2006-08-22 EP EP06782871.5A patent/EP1932855B1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1932855A4 (en) | 2009-12-02 |
| JP4261531B2 (ja) | 2009-04-30 |
| US8673839B2 (en) | 2014-03-18 |
| WO2007029484A1 (ja) | 2007-03-15 |
| CA2620132A1 (en) | 2007-03-15 |
| JP2007070277A (ja) | 2007-03-22 |
| EP1932855A1 (en) | 2008-06-18 |
| EP1932855B1 (en) | 2013-07-24 |
| US20090281029A1 (en) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8673839B2 (en) | Lactoferrin complex and method of producing the same | |
| JP6581157B2 (ja) | エリスロポエチンの多糖誘導体 | |
| CN104906594B (zh) | 用于与蛋白质和肽缀合的四个支链的树枝状大分子peg | |
| CA2698173C (en) | Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof | |
| JPH08510255A (ja) | 接合−安定化ポリペプチド組成物 | |
| Awwad et al. | The case for protein PEGylation | |
| CN101627056B (zh) | Y型聚乙二醇修饰的g-csf及其制备方法和应用 | |
| US20110009313A1 (en) | Polyethylene glycolated lactoferrin complex and method of producing the same | |
| KR101483814B1 (ko) | 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도 | |
| JP5460958B2 (ja) | タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法 | |
| JP2008069073A (ja) | ラクトフェリン複合体及びその製造方法 | |
| Balaei | Optimization of PEGylation condition of recombinant Interferon beta-1a | |
| KR102039493B1 (ko) | 신규 엑세나타이드 변이체-고분자 복합체 | |
| JP2016501886A (ja) | 高純度の治療用複合タンパク質の調製方法 | |
| Awwad et al. | 1UCL School of Pharmacy, London, United Kingdom, 2National Institute for Health Research (NIHR), Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200831 |